{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:24:37Z","timestamp":1761513877695},"reference-count":111,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Antigen-specific immunotherapies have emerged as important components of curative treatment algorithms for many cancers. In acute myeloid leukemia (AML), success has been less obvious. Nonetheless, among the few drugs shown to improve survival in recent randomized trials is the CD33 antibody\u2013drug conjugate gemtuzumab ozogamicin. Significant antileukemic activity is also well documented for radioimmunoconjugates targeting CD33, CD45, or CD66. These therapeutics can intensify conditioning before hematopoietic cell transplantation, but their effect on patient outcomes needs clarification. Emerging data now suggest clinical antileukemic activity of several novel antibodies and perhaps some adoptive T-cell immunotherapies and vaccines. In parallel, numerous other agents targeting a wider variety of antigens are currently being explored. However, the antigenic heterogeneity characteristic of AML is a considerable limitation for all these therapeutics, and many important questions related to the ideal target antigen(s), disease situation in which to use these therapies, most suitable patient populations, exact treatment modalities, and details of supportive care needs remain open. Addressing such questions in upcoming studies will be required to ensure that antigen-directed therapies become an effective tool in AML, a disease for which outcomes with standard \u201c3 + 7\u201d-based chemotherapy have remained unsatisfactory in many patients.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.584","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T11:23:25Z","timestamp":1473938605000},"page":"584-595","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Antigen-specific immunotherapies for acute myeloid leukemia"],"prefix":"10.1182","volume":"2015","author":[{"given":"Sarah A.","family":"Buckley","sequence":"first","affiliation":[{"name":"Hematology\/Oncology Fellowship Program,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, and"},{"name":"Department of Epidemiology, University of Washington, Seattle, WA; and"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"5","key":"2019111703524549000_B1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2019111703524549000_B2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cell.2012.02.034","article-title":"Antibody-based immunotherapy of cancer","volume":"148","author":"Weiner","year":"2012","journal-title":"Cell"},{"issue":"4","key":"2019111703524549000_B3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrc3907","article-title":"Haematological malignancies: at the forefront of immunotherapeutic innovation","volume":"15","author":"Bachireddy","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"2019111703524549000_B4","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/leu.2012.145","article-title":"Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia","volume":"26","author":"Anguille","year":"2012","journal-title":"Leukemia"},{"issue":"16","key":"2019111703524549000_B5","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","article-title":"Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML","volume":"119","author":"Pollard","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111703524549000_B6","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"issue":"26","key":"2019111703524549000_B7","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"key":"2019111703524549000_B8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/978-1-4939-1393-0_27","article-title":"Antibody-based therapeutics targeting CD33, CD45, and CD66","volume-title":"Targeted Therapy of Acute Myeloid Leukemia","author":"Walter","year":"2015"},{"issue":"9","key":"2019111703524549000_B9","first-page":"965","article-title":"Phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immunoglobulin M monoclonal antibody to CD15","volume":"1","author":"Ball","year":"1995","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111703524549000_B10","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cncr.21901","article-title":"Activity of alemtuzumab in patients with CD52-positive acute leukemia","volume":"106","author":"Tibes","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"2019111703524549000_B11","first-page":"1421","article-title":"Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia","volume":"4","author":"Caron","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111703524549000_B12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/sj.leu.2402803","article-title":"Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195","volume":"17","author":"Feldman","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"2019111703524549000_B13","first-page":"372","article-title":"Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia","volume":"6","author":"Jurcic","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111703524549000_B14","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1080\/10428190903050013","article-title":"Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial","volume":"50","author":"Raza","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2019111703524549000_B15","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","article-title":"Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia","volume":"23","author":"Feldman","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111703524549000_B16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3324\/haematol.2012.066613","article-title":"Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia","volume":"98","author":"Sekeres","year":"2013","journal-title":"Haematologica"},{"issue":"24","key":"2019111703524549000_B17","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2012-04-420596","article-title":"Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)","volume":"120","author":"Ossenkoppele","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111703524549000_B18","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3109\/10428194.2014.956316","article-title":"A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia","volume":"56","author":"He","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111703524549000_B19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/13543784.2013.739605","article-title":"Discontinued drugs in 2011: oncology drugs","volume":"22","author":"Williams","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"2019111703524549000_B20","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1200\/jco.2015.33.15_suppl.7059","article-title":"Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia [abstract]","volume":"33","author":"Sanford","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111703524549000_B21","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1182\/blood.V124.21.3756.3756","article-title":"KB004, a novel non-fucosylated humaneered antibody, targeting EphA3, is active and well tolerated in a phase I\/II study of advanced hematologic malignancies [abstract]","volume":"124","author":"Swords","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111703524549000_B22","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V124.21.386.386","article-title":"Targeting the CXCR4 pathway: safety, tolerability and clinical activity of ulocuplumab (BMS-936564), an anti-CXCR4 antibody, in relapsed\/refractory acute myeloid leukemia [abstract]","volume":"124","author":"Becker","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2019111703524549000_B23","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1182\/blood-2012-06-437558","article-title":"A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission","volume":"120","author":"Vey","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111703524549000_B24","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111703524549000_B25","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2741\/4181","article-title":"Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin","volume":"18","author":"Cowan","year":"2013","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"2","key":"2019111703524549000_B26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14712598.2011.543895","article-title":"Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy","volume":"11","author":"Breccia","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"2019111703524549000_B27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"32","key":"2019111703524549000_B28","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9825","key":"2019111703524549000_B29","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"21","key":"2019111703524549000_B30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood.V118.21.79.79","article-title":"Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study [abstract]","volume":"118","author":"Delaunay","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2019111703524549000_B31","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111703524549000_B32","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"issue":"27","key":"2019111703524549000_B33","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111703524549000_B34","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.V124.21.619.619","article-title":"Improved overall survival with gemtuzumab ozogamicin (GO) compared with best supportive care (BSC) in elderly patients with untreated acute myeloid leukemia (AML) not considered fit for intensive chemotherapy: final results from the randomized phase III study (AML-19) of the EORTC and Gimema Leukemia Groups [abstract]","volume":"124","author":"Amadori","year":"2014","journal-title":"Blood"},{"issue":"35","key":"2019111703524549000_B35","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1200\/JCO.2013.49.0771","article-title":"Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)","volume":"31","author":"Amadori","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111703524549000_B36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2012.229","article-title":"The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison","volume":"27","author":"Burnett","year":"2013","journal-title":"Leukemia"},{"issue":"13","key":"2019111703524549000_B37","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","article-title":"Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study","volume":"115","author":"L\u00f6wenberg","year":"2010","journal-title":"Blood"},{"issue":"20","key":"2019111703524549000_B38","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1182\/blood-2010-09-309229","article-title":"Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin","volume":"117","author":"Fernandez","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111703524549000_B39","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood-2012-03-416701","article-title":"Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004","volume":"120","author":"Hasle","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111703524549000_B40","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703524549000_B41","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood.V124.21.623.623","article-title":"Interim analysis of a phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia (AML) [abstract]","volume":"124","author":"Stein","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111703524549000_B42","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s10637-011-9670-0","article-title":"Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed\/refractory acute myeloid leukemia","volume":"30","author":"Lapusan","year":"2012","journal-title":"Invest New Drugs"},{"issue":"2","key":"2019111703524549000_B43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3324\/haematol.2012.071092","article-title":"Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195\/rGEL), in patients with advanced myeloid malignancies","volume":"98","author":"Borthakur","year":"2013","journal-title":"Haematologica"},{"issue":"21","key":"2019111703524549000_B44","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood.V120.21.3625.3625","article-title":"SL-401, a targeted therapy directed to the interleukin-3 receptor present on leukemia blasts and cancer stem cells, is active as a single agent in patients with advanced AML [abstract]","volume":"120","author":"Konopleva","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111703524549000_B45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2019111703524549000_B46","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1182\/blood-2014-01-492256","article-title":"Immunotoxins for leukemia","volume":"123","author":"Wayne","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111703524549000_B47","first-page":"72","article-title":"Immunotoxin resistance in multidrug resistant cells","volume":"63","author":"McGrath","year":"2003","journal-title":"Cancer Res"},{"issue":"3","key":"2019111703524549000_B48","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/imt.10.114","article-title":"Cancer radioimmunotherapy","volume":"3","author":"Sharkey","year":"2011","journal-title":"Immunotherapy"},{"issue":"20","key":"2019111703524549000_B49","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1158\/1078-0432.CCR-11-0483","article-title":"Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends","volume":"17","author":"Steiner","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2019111703524549000_B50","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1182\/blood-2013-10-492223","article-title":"Advances in the treatment of hematologic malignancies using immunoconjugates","volume":"123","author":"Palanca-Wessels","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2019111703524549000_B51","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/00007890-199211000-00012","article-title":"The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia","volume":"54","author":"Appelbaum","year":"1992","journal-title":"Transplantation"},{"issue":"6","key":"2019111703524549000_B52","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bmt.1704201","article-title":"Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias","volume":"32","author":"Burke","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111703524549000_B53","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V94.4.1237","article-title":"Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome","volume":"94","author":"Matthews","year":"1999","journal-title":"Blood"},{"issue":"5","key":"2019111703524549000_B54","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood-2005-06-2317","article-title":"131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission","volume":"107","author":"Pagel","year":"2006","journal-title":"Blood"},{"issue":"27","key":"2019111703524549000_B55","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1182\/blood-2009-03-213298","article-title":"Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"114","author":"Pagel","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111703524549000_B56","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.bbmt.2014.05.014","article-title":"Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome","volume":"20","author":"Mawad","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111703524549000_B57","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1080\/1042819021000033015","article-title":"188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia","volume":"43","author":"Bunjes","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111703524549000_B58","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1182\/blood.V99.6.2270","article-title":"Transplantation-related toxicity and acute intestinal graft-versus-host disease after conditioning regimens intensified with Rhenium 188-labeled anti-CD66 monoclonal antibodies","volume":"99","author":"Klein","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2019111703524549000_B59","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-2141.2005.05663.x","article-title":"188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study","volume":"130","author":"Ringhoffer","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111703524549000_B60","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s12185-008-0043-1","article-title":"Radioimmunotherapy with [(188)Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia","volume":"87","author":"Koenecke","year":"2008","journal-title":"Int J Hematol"},{"key":"2019111703524549000_B61","first-page":"441","article-title":"Targeted radionuclide therapy for leukemia","volume-title":"Targeted Radionuclide Therapy","author":"Walter","year":"2011"},{"issue":"2","key":"2019111703524549000_B62","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/cbr.2010.0759","article-title":"Pretargeted radioimmunotherapy for hematologic and other malignancies","volume":"25","author":"Walter","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"key":"2019111703524549000_B63","first-page":"44","article-title":"Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry","volume":"1","author":"van de Watering","year":"2014","journal-title":"Front Med (Lausanne)"},{"key":"2019111703524549000_B64","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.bbmt.2012.11.054","article-title":"Pretargeted radioimmunotherapy using an anti-CD45 antibody-streptavidin conjugate and radiolabeled DOTA-biotin in patients with high-risk acute leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation [abstract]","volume":"19","author":"Mawad","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111703524549000_B65","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.14694\/EdBook_AM.2014.34.e126","article-title":"Targeted alpha-particle immunotherapy for acute myeloid leukemia","author":"Jurcic","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"2019111703524549000_B66","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","article-title":"Targeted alpha particle immunotherapy for myeloid leukemia","volume":"100","author":"Jurcic","year":"2002","journal-title":"Blood"},{"issue":"21","key":"2019111703524549000_B67","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-10-0382","article-title":"Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia","volume":"16","author":"Rosenblat","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2019111703524549000_B68","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood.V118.21.768.768","article-title":"Phase I trial of the targeted-particle nano-generator actinium 225 (225Ac)-lintuzumab (anti-CD33; HuM195) in acute myeloid leukemia (AML) [abstract]","volume":"118","author":"Jurcic","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111703524549000_B69","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood.V122.21.1460.1460","article-title":"Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac)-lintuzumab (anti-CD33) in combination with low-dose cytarabine (LDAC) for older patients with untreated acute myeloid leukemia (AML) [abstract]","volume":"122","author":"Jurcic","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111703524549000_B70","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11899-015-0250-9","article-title":"Update on antigen-specific immunotherapy of acute myeloid leukemia","volume":"10","author":"Buckley","year":"2015","journal-title":"Current Hematol Malig Rep"},{"issue":"22","key":"2019111703524549000_B71","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood-2014-04-569061","article-title":"Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells","volume":"124","author":"Romain","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111703524549000_B72","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1182\/blood.V124.21.120.120","article-title":"First-in man, phase 1 study of CSL362 (anti-IL3R\u03b1 \/ anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia (AML) in CR at high risk for early relapse [abstract]","volume":"124","author":"Smith","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111703524549000_B73","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2019111703524549000_B74","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2019111703524549000_B75","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood.V124.21.2321.2321","article-title":"The antibody-drug conjugate (ADC) IMGN779 is highly active in vitro and in vivo against acute myeloid leukemia (AML) with FLT3-ITD mutations [abstract]","volume":"124","author":"Whiteman","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111703524549000_B76","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/35101072","article-title":"Improving the efficacy of antibody-based cancer therapies","volume":"1","author":"Carter","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2019111703524549000_B77","first-page":"12","article-title":"Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on","author":"Riethm\u00fcller","year":"2012","journal-title":"Cancer Immun"},{"issue":"12","key":"2019111703524549000_B78","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res"},{"issue":"4","key":"2019111703524549000_B79","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/leu.2013.18","article-title":"Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells","volume":"27","author":"Arndt","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"2019111703524549000_B80","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/leu.2012.341","article-title":"T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33\/CD3-bispecific BiTE antibody construct","volume":"27","author":"Aigner","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2019111703524549000_B81","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","article-title":"Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML","volume":"123","author":"Laszlo","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111703524549000_B82","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1158\/1535-7163.MCT-13-0956","article-title":"Preclinical characterization of AMG 330, a CD3\/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia","volume":"13","author":"Friedrich","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"2019111703524549000_B83","doi-asserted-by":"crossref","first-page":"e0135945","DOI":"10.1371\/journal.pone.0135945","article-title":"The broad anti-AML activity of the CD33\/CD3 bispecific BiTE antibody construct, AMG 330, is impacted by disease stage and risk","volume":"10","author":"Harrington","year":"2015","journal-title":"PLoS One"},{"key":"2019111703524549000_B84","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2013.1.348","article-title":"T-cell adoptive immunotherapy for acute lymphoblastic leukemia","volume":"2013","author":"Fry","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9967","key":"2019111703524549000_B85","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"16","key":"2019111703524549000_B86","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111703524549000_B87","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol Ther"},{"issue":"20","key":"2019111703524549000_B88","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2019111703524549000_B89","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/blood-2014-11-612721","article-title":"Targeting of folate receptor-beta on acute myeloid leukemia blasts with chimeric antigen receptor expressing T cells","volume":"125","author":"Lynn","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111703524549000_B90","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.12282","article-title":"Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor","volume":"161","author":"Tettamanti","year":"2013","journal-title":"Br J Haematol"},{"issue":"18","key":"2019111703524549000_B91","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"issue":"15","key":"2019111703524549000_B92","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111703524549000_B93","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2019111703524549000_B94","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2014.112748","article-title":"Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia","volume":"100","author":"O'Hear","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"2019111703524549000_B95","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2019111703524549000_B96","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"issue":"21","key":"2019111703524549000_B97","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood.V124.21.3939.3939","article-title":"Transferred donor-derived virus specific CD8+ T cells that have been transduced to express a WT1-specific T cell receptor can persist and provide anti-leukemic activity in AML patients post-transplant [abstract]","volume":"124","author":"Bar","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111703524549000_B98","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2013-04-496844","article-title":"Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)","volume":"122","author":"Greiner","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111703524549000_B99","first-page":"90a","article-title":"PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia [abstract]","volume":"110","author":"Qazilbash","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111703524549000_B100","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","article-title":"Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies","volume":"111","author":"Rezvani","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111703524549000_B101","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2007-07-099366","article-title":"RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses","volume":"111","author":"Schmitt","year":"2008","journal-title":"Blood"},{"issue":"26","key":"2019111703524549000_B102","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","article-title":"A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS","volume":"113","author":"Keilholz","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111703524549000_B103","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood-2009-10-250993","article-title":"Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia","volume":"116","author":"Maslak","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111703524549000_B104","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1517\/13543784.2014.889114","article-title":"WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy","volume":"23","author":"Rein","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"2019111703524549000_B105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jca.10080","article-title":"Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation","volume":"19","author":"Lee","year":"2004","journal-title":"J Clin Apher"},{"issue":"4","key":"2019111703524549000_B106","first-page":"855","article-title":"Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts","volume":"28","author":"Li","year":"2006","journal-title":"Int J Oncol"},{"issue":"2","key":"2019111703524549000_B107","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2141.2006.05997.x","article-title":"Phase I\/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia","volume":"133","author":"Roddie","year":"2006","journal-title":"Br J Haematol"},{"issue":"31","key":"2019111703524549000_B108","doi-asserted-by":"crossref","first-page":"13824","DOI":"10.1073\/pnas.1008051107","article-title":"Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination","volume":"107","author":"Van Tendeloo","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"2019111703524549000_B109","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood.V122.21.236.236","article-title":"Prevention of relapse in acute myeloid leukemia by dendritic cell vaccination: report on a phase II study with 29 patients [abstract]","volume":"122","author":"Berneman","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703524549000_B110","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1182\/blood.V122.21.3928.3928","article-title":"Clinical trial evaluating DC\/AML fusion cell vaccination in AML patients [abstract]","volume":"122","author":"Rosenblatt","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703524549000_B111","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood.V122.21.2651.2651","article-title":"Clinical and immunological results of a phase I\/IIa study of allogeneic dendritic cell (DC) vaccination, an \u201coff the shelf\u201d treatment to prevent or delay relapse in elderly patients with acute myeloid leukemia [abstract]","volume":"122","author":"van de Loosdrecht","year":"2013","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/584\/1250399\/bep00115000584.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/584\/1250399\/bep00115000584.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T03:53:19Z","timestamp":1573962799000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/584\/20674\/Antigenspecific-immunotherapies-for-acute-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.584","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}